Leading the way in corneal therapy

Clarke has had the great fortune to work with a diverse and amazing group of people throughout his career. Clarke is a seasoned international biopharmaceutical Chief Executive with experience in company foundation and the licensing of products and technologies. He has a proven ability to build, lead and rapidly integrate diverse organizations as well as extensive experience in the development of products from concept through to Phase III and submission, across multiple disease areas. Clarke has a history of successfully launching novel therapies, managing mature products and maximizing profitability of product portfolios.

Dr. Dana is Senior Scientist and the Claes Dohlman Professor of Ophthalmology at Harvard Medical School, Director of the Cornea Service at the Massachusetts Eye and Ear, Vice Chairman of Harvard Ophthalmology for Academic Programs, Director of the Laboratory of Ocular Immunology, Transplantation and Regeneration, member of the Harvard Medical School graduate program in Immunology, and Director of the Harvard-Vision Clinical Scientist Development Program. A graduate of Johns Hopkins University and Harvard University, he has subspecialty training in both corneal diseases and ocular immunology. He is a clinician-scientist whose contributions to the fields of transplantation, regenerative medicine, angiogenesis, and ocular surface disease have led to 500+ publications, which have been cited more than 46,000 times. He is the recipient of numerous top international honors in the field of vision science and has received Harvard Medical School’s top mentoring award. Apart from over 100 clinical trainees, he has trained more than 150 scientists from 36 countries in his laboratory to date; many are professors, senior scientists, division/department chiefs and leaders in industry. Dr. Dana has been the scientific co-founder of several biotech firms.

Dr. Chauhan is an Associate Professor in the Harvard Medical School Department of Ophthalmology, with a scientist appointment at Massachusetts Eye and Ear and an affiliated faculty at the Harvard Stem Cell Institute. Working at the intersection of immunology, stem cell biology, and regenerative medicine, Dr. Chauhan's research for the past 20 years has focused on determining the functions of different immune and non-immune cells in promoting immune quiescence and tissue regeneration. His research helped establish that mesenchymal stem cells (MSC) promote tissue regeneration by secreting high levels of hepatocyte growth factor (HGF), suggesting a novel HGF-based approach that could potentially eliminate the need for cell-based and conventional therapies for ocular diseases. Dr. Chauhan's research program is funded by several NEI/NIH and Department of Defense grants and awards. He has published over 120 papers, patents, and applications, which have led to multiple licenses to biotech companies.

Dr. Fisher is a partner with the Mass General Brigham Ventures, focusing on early-stage investments and company creation. Previously, she was in the private/family office at Bracebridge Capital serving as Director of Private Investments, where she led investments in early-stage life science companies. Prior to that role, she led business development for Ginkgo BioWorks and was Senior Director at PureTech Ventures. She spent several years working as a scientist in anti-viral drug discovery for Idenix Pharmaceuticals and Anadys Pharmaceuticals.

Dr. Fisher received her undergraduate degree from Mount Holyoke College, her MBA from the MIT Sloan School of Management, and her PhD from Harvard University. While at Harvard, she co-founded Harvard Graduate Women in Science and Engineering (HGWISE). Dr. Fisher represents Mass General Brigham Ventures on the boards of Mediar, Nocion, Claris Bio, and ZielBio as well as serving as an observer for Scorpion and Amolyt.

Mr. de Garidel is a highly experienced biopharmaceutical senior executive who has served as CEO for several biopharmaceutical companies at different stages of development for the last 13 years, including two significant billion dollar exits with CinCor Pharma and Corvidia Therapeutics in the last 3 years. He is currently Chairman of Ipsen Group, a public European pharmaceutical company developing and marketing products in several therapeutic areas. Before becoming a full-time Chairman of Ipsen, he was Chairman and CEO of Ipsen from 2010 to 2016. Earlier in his career, Mr. de Garidel played a key role in the development of Amgen in Europe as regional Vice President. Mr. de Garidel serves on the board of a few biotech companies, including Ipsen, CinCor Pharma (until its sale to AstraZeneca), and Claris Bio.

Mr. de Garidel earned a Master’s in International Management at Thunderbird School of Global Management and attended the Advanced Management Program at Harvard Business School.

Dr. Harrison serves as a member of the Claris board of directors and is a partner with Novo Ventures (US) Inc. in San Francisco, California. Dr. Harrison currently also serves on the boards of Aristea Therapeutics, Edgewise Therapeutics (NASDAQ:EWTX), Glycomine, Hummingbird Bioscience, Nuvig Therapeutics, and Rondo Thrapeutics. He was previously on the board or was involved with investments in Bolt Biotherapeutics (NASDAQ:BOLT), Reneo Pharmaceuticals (NASDAQ:RPHM), Mirum Pharma (NASDAQ: MIRM), Allievex, and Vertuis Bio (acquired). Prior to joining Novo Ventures, Dr. Harrison worked in commercial planning and strategy at Genentech, where he was a member of the HER2 franchise and Ophthalmology franchise teams. Dr. Harrison was a life sciences management consultant at L.E.K. Consulting and a seed-stage investor at Mission Bay Capital, where he helped create programs to launch and build life sciences companies in the San Francisco Bay Area.

Dr. Harrison and earned a PhD in Pharmacology from Yale University and studied cellular lipid storage and metabolism as an A.P. Giannini Foundation Fellow at the J. David Gladstone Institutes.

Agustin Mohedas is a Portfolio Manager and Research Analyst on the Health Care Team at Janus Henderson Investors. He is focused primarily on the biotechnology sector. Before joining the firm as a research analyst in 2019, Agustin was a senior analyst at Eventide Asset Management, working on the Healthcare and Life Sciences Fund from 2017. Prior to this, he was an analyst with RA Capital Management, a long/short hedge fund focused on biotechnology, from 2014.
Agustin received his bachelor of science degree in biomedical engineering from Texas A&M University, graduating summa cum laude. He also earned a PhD in medical engineering and medical physics from the Harvard-MIT Program in Health Sciences and Technology. His PhD research focused on drug development for a rare genetic disease, resulting in multiple patents and publications. He has 10 years of financial industry experience.